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Background:  Spontaneous infarct-related artery (IRA) recanalization before primary percutaneous coronary intervention (PCI) favorably impacts 
outcome. However, the role of IRA patency after early abciximab administration in patients with ST-segment elevation myocardial infarction (STEMI) 
transferred for primary PCI is still a matter of debate.
Methods:  Data were gathered for 1,650 consecutive STEMI patients transferred for primary PCI from hospital networks in 7 countries in Europe. 
We identified 691 patients who were pretreated with abciximab before transportation to cathlab hospital and underwent PCI. Angiography showed 
early IRA patency (TIMI flow 2 or 3) in 233 patients (33.7%) and occluded IRA (TIMI flow 0 or 1) in 458 patients (66.3%).
Results:  Higher rate of TIMI 3 flow after PCI and ECG ST-segment resolution >50% after PCI was found in patients with patent IRA in baseline 
angiography (TIMI 3: 96.6% vs 92.1% p=0.024; STR: 89.3% vs 79.9% p=0.002). One-year mortality was significantly lower in patients with patent 
IRA (Figure). In multivariable Cox regression analysis IRA patency at baseline was identified as an independent predictor of 1-year mortality.
Conclusions:  In STEMI patients, early IRA recanalization after abciximab administration before transfer for primary PCI is associated with better 
postprocedural myocardial perfusion and lower 1-year mortality. 
